PCI Pharma Services has announced a successful collaboration with ChiRhoClin, Inc., a theranostics specialist, to prevent a potential shortage of ChiRhoStim (Human Secretin for Injection), a critical diagnostic drug used for testing pancreatic diseases and cancer. The partnership aims to
Scorpius Holdings, Inc. (NYSE American: SCPX) has announced the launch of a new business unit, Scorpius Ventures, which will help emerging biotech companies onshore the production of biologics. This initiative is designed to ease financial constraints for biotech firms by
Ardena, a pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has announced the full GMP approval of its newly expanded nanomedicine manufacturing facility in Oss. This approval, granted by the Dutch Healthcare Authority, is a significant milestone for the company in
C Ray Therapeutics (Chengdu) Co., Ltd., an enterprise specialising in radiopharmaceuticals, has completed a Series A+ financing round exceeding $100 million. The round was co-led by Shenzhen Capital Group Co., Ltd. (SCGC) and TaiLong Capital, with participation from GL Ventures,
ProcureTech in the Real World: Online Meetup
19th Feb 2025
Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and clinical genetics, she brings over 15 years of experience in genetic therapy research across Europe,
WuXi AppTec, a global life sciences and pharmaceutical services company, announced that its Couvet, Switzerland facility has received a silver medal in the 2024 EcoVadis business sustainability ratings. This achievement places the facility in the top 9% of all companies
GenScript Biotech, a global biotechnology company, has announced that its CDMO subsidiary, ProBio, has licensed its proprietary PD-1 new molecular entity (NME) to LaNova Medicines. This licensing agreement has paved the way for LaNova’s PD-1/VEGF bispecific antibody program, LM-299, which
Cellectar Biosciences has announced a decade-long supply agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225 (Ac-225), a key radioisotope in cancer treatment. This agreement is set to provide Cellectar with a stable Ac-225 supply, enabling
SEKISUI Diagnostics has announced the completion of a £15.7 million expansion of its cGMP-certified microbial manufacturing facility in the UK. This new capacity, pending licensing, will enable production of clinical-grade substances for enzyme, protein, antibody fragment, and plasmid-based therapies, including
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
